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Biomarkers in Acute Cardiac Disease
In their state-of-the-art paper on biomarkers in acute cardiac
disease (1), Dr. Jaffe and colleagues list creatine kinase-MB
(CK-MB) as a “potentially outdated marker.” However, CK-MB
has a specific utility in the diagnosis of reinfarction (2), and it
cannot be replaced by the cardiac troponins for this purpose. By
following up the time course of rise and fall of CK-MB, an
interruption in the progressive decline in the level of the biomarker
(to levels below upper reference limit) can be detected (2–4).
Re-elevations in CK-MB by more than 50%, can be used to
diagnose re-infarctions as early as 18 h after the index event (2).
Both cardiac troponin T (cTnT) and cardiac troponin I (cTnI) on
the other hand are continuously released from degenerating con-
tractile apparatus in necrotic cardiomyocytes and may show per-
sistent elevations, 7 to 10 days in the case of cTnI and up to 10 to
14 days in the case of cTnT, after the index event (2). The
protracted time course of kinetic release of cTnI and cTnT limit
their ability to diagnose reinfarction even several days after the
index ST-segment elevation myocardial infarction (STEMI) be-
cause the cardiac troponin levels will still be on the rise during this
period as a result of their normal kinetics, and it is not possible to
be sure whether the rise is due to a re-infarction or not. It is
because of this important difference in the kinetics between
CK-MB, which shows a rapid rise and fall, and the troponins, the
American College of Cardiology/American Heart Association
Practice guidelines for STEMI specifically state that CK-MB is
superior for diagnosing reinfarction (2). This is very relevant as
recurrent chest pain is a common complaint of patients admit-
ted for myocardial ischemia and CK-MB plays a vital role in the
further evaluation of this complaint.
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REPLY
Drs. Fye, Nagajothi, and Trivedi raise important issues that we are
pleased to address.
One that many of us have tried to reinforce for years is that
elevations of biomarkers of cardiac injury are not synonymous with
myocardial infarction (1). This is especially important for cardiac
troponin which, because it is more sensitive than creatine kinase
MB (CKMB), detects cardiac injury in many situations which are
not due to primary coronary abnormalities. Thus, many patients
with elevations do not require the extensive workups Dr. Fye
correctly indicates can occur if one obviates common sense. Some
may need an evaluation for pulmonary embolism or myocarditis
and some only watchful waiting. Some of this can occur in the
outpatient setting in our view, but we often see cardiologists
assume that once the patient is discharged that they can forget
about elevations. Neglecting such a potent risk factor for mortality
is not good common sense either. Regardless of the etiology,
elevations of troponin are indicative of significant cardiovascular
disease and usually are associated with an adverse prognosis in the
short term (2) and over time once recovery occurs (3) and in those
who are more compensated (4). When such elevations occur in
critically ill individuals, first efforts should be focused on the
primary disease process which very often is the stimulus for the
cardiac injury. Additional work is necessary to distinguish when we
as cardiologists should address cardiac issues acutely over and
above treating the underlying disease state. Many of us are actively
involved in trying to define such subsets at present. Whether or not
acute intervention is needed, it is clear from most studies that
elevations of troponin also predict adverse long term events (3,4).
Thus, those who were critically ill and recover and those in whom
“incidental” elevations of troponin were detected, require careful
evaluation. That could mean an evaluation for ischemic heart
disease but as Dr. Fye suggests, it is prudent to consider other
etiologies for elevations as well.
It is also good common sense to upgrade our clinical judgment
periodically. It is thus prudent in considering the possibility in a
given patient of ischemic heart disease to take note of information
concerning the lack of perfection of the angiogram, (5) differences
in the way in which women present with infarction, (6) and the
recent article in the Journal of the American College of Cardiology
suggesting the high frequency of unrecognized myocardial infarc-
tions detected in older individuals by MRI (7).
The issue of reinfarction is one where we have used common
sense. The state of the art and guidelines are not the same. The
later are often much more conservative. It was presumed in the
initial studies, that increases in CKMB post-infarction were
indicative of reinfarction. There was no independent validation of
that. There has been no validation of the use of increases on the
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down slope at all and those criteria are likely very insensitive. We
now know that reinfarction is easily detected with troponin by the
presence of a rising pattern of values (8). In the vast majority of
patients, changes in troponin, presuming sensitive assays and
recommended cut off values, occur rapidly, obviating the delay in
the occasional patient in whom decision making might depend
on the values (9). Because troponin is more sensitive, it should
provide a clearer signal on the down slope than CKMB and
several groups are considering a recommendation of a 20% to
25% change in that situation. Those criteria too will likely be
insensitive but will prevent false-positive diagnoses as well.
Once one starts to rely on troponin values, the ease with which
they can be used becomes easily appreciated and their use becomes
part of good common sense. Hanging onto the past adds costs and
retards the ability of clinicians to learn how easily many of these
issues can be resolved.
The issue Dr. Fye highlights is that we need to be smarter about
how we respond to elevations of troponin both acutely and longer
term. Troponin elevations should never trump common sense, but
we must also be open to the possibility that at times, especially in
a busy world, we may need to allow our common sense to evolve
as the science of our discipline improves and to acknowledge a
responsibility to work up patients with abnormal troponin values as
outpatients when appropriate rather than ignore such elevations.
All of that would be good common sense.
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